glp 1 and eye disease Do GLP-1 Medications Cause Problems? Understanding the NAION Risk – Revolution Health & Wellness GLP-1 Receptor Agonists and the
Description
Who is at risk of NAFLD
A., & Higgins, J
- Moderate to vigorous bouts (210 min): typically 35 days per week
Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity since the US Food & Drug Administration first approved semaglutide (brand name Ozempic/Wegovy) for weight loss in 2021
All subjects recovered before follow-up, most during semaglutide treatment and some after treatment
